Current Science

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Antitumour efficacy of (-)epigallocatechin-3-gallate (EGCG) was evaluated in vitro against the cancer cell lines BxPC-3 (pancreatic cancer), A549 (lung cancer), SH-SY5Y (neuroblastoma), MDA-MB-231 and MCF-7 (breast cancer); in vivo in nude mice by tumour growth inhibition of pancreatic cancers (BxPC-3, MIAPaCa-2), breast cancer (MDA-MB-231), and in silico by docking studies. EGCG significantly inhibited these cancer cell lines in vitro and showed significant tumour reduction in vivo. EGCG docked on to the Her-2 receptor (1N8Y) and the tubulin dimer receptor at a site other than the existing docetaxel ligand. Overall our results suggest that EGCG has potent antineoplastic activity.

Keywords

Antitumour Efficacy, Breast Cancer, Docking, Epigallocatechin Gallate, Lung Cancer.
User
Notifications
Font Size